|Articles|August 24, 2022

physIQ Announces Collaboration with InCarda Therapeutics and Syneos Health

physIQ has announced a strategic collaboration with InCarda Therapeutics, Inc. Syneos Health recommended physIQ’s monitoring solution to help advance InCarda’s clinical study of InRhythm™ (orally inhaled flecainide) in patients with atrial fibrillation.

Read more about the new partnership here.

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe

Related Content

© Sergey Nivens - © Sergey Nivens - stock.adobe.com

Data Quality Across the Clinical Trial Lifecycle: What It Takes to Fully Trust Your Data

ByAndy Studna, Senior Editor

August 13th 2026

ACT Brief: Training Completion Versus Execution Readiness, AI Monitoring Agent Financial Value at Scale, and FDA Warning Letters and AI Oversight Gaps

ByAndy Studna, Senior Editor

August 13th 2026

Tufts CSDD Analysis Finds AI Clinical Monitoring Agent Can Generate Up to $21 Million in Net Financial Value Per Drug Development Program

ByAndy Studna, Senior Editor

August 12th 2026

Beyond Compliance: ProofPilot's Joseph Kim and Lauren Briggs on Making Clinical Trial Training Actually Work

ByOtis Johnson, PhD, MPA,Andy Studna, Senior Editor,Joseph Kim,Lauren Briggs

August 12th 2026

ACT Brief: Efficacy Ceiling Breakthrough in Autoimmune Disease, Early-Career Retention and Burnout Prevention, and PRV Program Catalyzing Rare Disease Investment

ByAndy Studna, Senior Editor

August 12th 2026

physIQ Announces Collaboration with InCarda Therapeutics and Syneos Health

Related Content

Data Quality Across the Clinical Trial Lifecycle: What It Takes to Fully Trust Your Data

ACT Brief: Training Completion Versus Execution Readiness, AI Monitoring Agent Financial Value at Scale, and FDA Warning Letters and AI Oversight Gaps

Tufts CSDD Analysis Finds AI Clinical Monitoring Agent Can Generate Up to $21 Million in Net Financial Value Per Drug Development Program

Beyond Compliance: ProofPilot's Joseph Kim and Lauren Briggs on Making Clinical Trial Training Actually Work

ACT Brief: Efficacy Ceiling Breakthrough in Autoimmune Disease, Early-Career Retention and Burnout Prevention, and PRV Program Catalyzing Rare Disease Investment

Trending on Applied Clinical Trials Online

Tufts CSDD Analysis Finds AI Clinical Monitoring Agent Can Generate Up to $21 Million in Net Financial Value Per Drug Development Program

Beyond Compliance: ProofPilot's Joseph Kim and Lauren Briggs on Making Clinical Trial Training Actually Work

ACT Brief: Efficacy Ceiling Breakthrough in Autoimmune Disease, Early-Career Retention and Burnout Prevention, and PRV Program Catalyzing Rare Disease Investment

The Career They Didn't Train For: Rethinking Early-Career Burnout in Clinical Research

Breaking the Efficacy Ceiling in IBD and Beyond